DCGI Attracts Further Controversy

BMI View: The regulatory environment of India's pharmaceutical market is far below international standards. Rules are poorly designed and implemented improperly. Our key concerns are a lack of appreciation of the risk/reward profiles of modern medicines and personnel working under challenging conditions, where corruption and bureaucracy are endemic. We expect regulatory reforms to be implemented, albeit slowly, so that India's pre-eminence as a clinical trial destination can be maintained.

To read the full article, please choose one of the following options: